Dr. Bourla said the drugmaker will produce 30 million courses by the end of the second quarter, with 6 million to 7 million being produced by the end of the first quarter, according to a tweet from Rebecca Robbins, a reporter for The New York Times. Dr. Bourla said Pfizer will produce approximately 45 million courses for both the third and fourth quarters.
The estimates given by Dr. Bourla cover Pfizer’s manufacturing for all global customers; only a fraction of the pills will go to the U.S.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.